# FDA 483 - Charles E. Canter, MD - December 20, 2021

Source: https://www.keypedia.com/records/483/charles-e-canter-md/3739e1ab-0947-4197-8742-1224c092b222

> FDA 483 for Charles E. Canter, MD on December 20, 2021. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Charles E. Canter, MD
- Inspection Date: 2021-12-20
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West II
- Summary: An FDA inspection of Charles E. Canter, MD in St Louis, MO, a clinical investigator site, revealed significant deficiencies in the conduct of an investigational study. Observations included failures to confirm subject exclusion criteria, document investigator review of eligibility, and confirm end-of-study visits. Additionally, inadequate investigational drug disposition records and incomplete case histories were noted.

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/karen-m-montgomery/ee91b1bb-8d51-4fdc-bee5-949441136e59)

Company: https://www.keypedia.com/companies/charles-e-canter-md/be438b40-ad13-48b4-a587-f0adefd8e1c9

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-operations-west-ii/8851d151-0390-4d17-be66-fd86d12aa6b8